AR043216A1 - Esteres activados de polietilenglicol - Google Patents
Esteres activados de polietilenglicolInfo
- Publication number
- AR043216A1 AR043216A1 ARP040100501A ARP040100501A AR043216A1 AR 043216 A1 AR043216 A1 AR 043216A1 AR P040100501 A ARP040100501 A AR P040100501A AR P040100501 A ARP040100501 A AR P040100501A AR 043216 A1 AR043216 A1 AR 043216A1
- Authority
- AR
- Argentina
- Prior art keywords
- polyethylene glycol
- oxalate
- esters
- active
- peg
- Prior art date
Links
- 239000002202 Polyethylene glycol Substances 0.000 title abstract 6
- 229920001223 polyethylene glycol Polymers 0.000 title abstract 6
- 150000002148 esters Chemical class 0.000 title abstract 3
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- BLFDUYCQDOOMSP-UHFFFAOYSA-N 2-oxo-2-(trifluoromethoxy)acetic acid Chemical compound FC(F)(F)OC(C(=O)O)=O BLFDUYCQDOOMSP-UHFFFAOYSA-N 0.000 abstract 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- OMAHFYGHUQSIEF-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) oxalate Chemical compound O=C1CCC(=O)N1OC(=O)C(=O)ON1C(=O)CCC1=O OMAHFYGHUQSIEF-UHFFFAOYSA-N 0.000 abstract 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 abstract 1
- 150000003901 oxalic acid esters Chemical class 0.000 abstract 1
- 230000006320 pegylation Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
- Polyesters Or Polycarbonates (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44835403P | 2003-02-19 | 2003-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043216A1 true AR043216A1 (es) | 2005-07-20 |
Family
ID=32908577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100501A AR043216A1 (es) | 2003-02-19 | 2004-02-18 | Esteres activados de polietilenglicol |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7094872B2 (enExample) |
| EP (1) | EP1597299A2 (enExample) |
| JP (1) | JP2006517995A (enExample) |
| AR (1) | AR043216A1 (enExample) |
| BR (1) | BRPI0407511A (enExample) |
| CA (1) | CA2515612A1 (enExample) |
| MX (1) | MXPA05008785A (enExample) |
| TW (1) | TW200426155A (enExample) |
| WO (1) | WO2004074345A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60041715D1 (de) | 1999-12-22 | 2009-04-16 | Nektar Therapeutics Al Corp | Verfahren zur herstellung von 1-benzotriazolcarbonatestern von wasserlöslichen polymeren |
| ES2291613T3 (es) * | 2002-01-16 | 2008-03-01 | Biocompatibles Uk Limited | Conjugados de polimeros. |
| GB0301014D0 (en) * | 2003-01-16 | 2003-02-19 | Biocompatibles Ltd | Conjugation reactions |
| ITPD20040159A1 (it) * | 2004-06-21 | 2004-09-21 | Univ Degli Studi Trieste | Derivati bifunzionali del polietilenglicole loro preparazione e uso. |
| US8133707B2 (en) * | 2006-01-17 | 2012-03-13 | Enzon Pharmaceuticals, Inc. | Methods of preparing activated polymers having alpha nitrogen groups |
| JP2007209543A (ja) * | 2006-02-09 | 2007-08-23 | Hidetoshi Tsuchida | 表面修飾アルブミンからなる固相膜および酸素吸着膜 |
| JP2009533347A (ja) | 2006-04-07 | 2009-09-17 | ネクター セラピューティックス エイエル，コーポレイション | 抗ＴＮＦα抗体の複合体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342832A (en) * | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
| US5618697A (en) * | 1982-12-10 | 1997-04-08 | Novo Nordisk A/S | Process for preparing a desired protein |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| CA2102808A1 (en) * | 1991-05-10 | 1992-11-11 | Hanne Bentz | Targeted delivery of bone growth factors |
| US5281698A (en) * | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5650234A (en) * | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6180095B1 (en) * | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
-
2004
- 2004-02-13 CA CA002515612A patent/CA2515612A1/en not_active Abandoned
- 2004-02-13 BR BRPI0407511-0A patent/BRPI0407511A/pt not_active IP Right Cessation
- 2004-02-13 JP JP2006502450A patent/JP2006517995A/ja not_active Withdrawn
- 2004-02-13 EP EP04710945A patent/EP1597299A2/en not_active Withdrawn
- 2004-02-13 WO PCT/IB2004/000424 patent/WO2004074345A2/en not_active Ceased
- 2004-02-13 MX MXPA05008785A patent/MXPA05008785A/es not_active Application Discontinuation
- 2004-02-18 TW TW093103934A patent/TW200426155A/zh unknown
- 2004-02-18 AR ARP040100501A patent/AR043216A1/es unknown
- 2004-02-19 US US10/782,268 patent/US7094872B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1597299A2 (en) | 2005-11-23 |
| CA2515612A1 (en) | 2004-09-02 |
| JP2006517995A (ja) | 2006-08-03 |
| MXPA05008785A (es) | 2005-10-18 |
| WO2004074345A2 (en) | 2004-09-02 |
| WO2004074345A3 (en) | 2005-01-20 |
| BRPI0407511A (pt) | 2006-02-14 |
| US7094872B2 (en) | 2006-08-22 |
| TW200426155A (en) | 2004-12-01 |
| US20040162388A1 (en) | 2004-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0695759T3 (da) | Peptapeptid-methylestere, der inhiberer human cancer | |
| CY1116980T1 (el) | Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf | |
| EP2298331A3 (en) | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins | |
| PE20020908A1 (es) | Produccion recombinante de polimeros polianionicos y uso de de los mismos | |
| WO2006081249A8 (en) | Conjugates of biologically active proteins having a modified in vivo half-life | |
| CY1114244T1 (el) | Σκευασματα ανταγωνιστη vegf καταλληλα για ενδοϋαλωδη χορηγηση | |
| ATE252601T1 (de) | Lang wirkende insulinotrope peptide | |
| PE20110236A1 (es) | Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina | |
| EP2062976A3 (en) | Site specific incorporation of keto amino acids into proteins | |
| EA200701913A1 (ru) | Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом | |
| ES2051806T3 (es) | Preparados de proteina humana estables. | |
| EA201000746A1 (ru) | Система трансдермальной доставки, способ трансдермального введения и способ изготовления системы трансдермальной доставки | |
| NZ591261A (en) | Improvements in the absorption of therapeutic agents across mucosal membranes or the skin | |
| DE60332277D1 (de) | Verabreichung von sirnas | |
| WO2001041812A3 (en) | Amphiphilic polymers and polypeptide conjugates comprising same | |
| DE60234921D1 (de) | Verabreichung von in lipidvesikeln verpackten kleinen hydrophilen molekülen | |
| BR0009472A (pt) | Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas | |
| NO20073914L (no) | Biologisk aktive peptider | |
| AR043216A1 (es) | Esteres activados de polietilenglicol | |
| EP1080724A4 (en) | COMPOSITIONS FOR REDUCING MTP ACTIVITY | |
| ATE474589T1 (de) | Angiogene peptide und ihre verwendungen | |
| EA200701228A1 (ru) | Стабильные композиции фенофибрата с эфирами жирных кислот | |
| RU2003125460A (ru) | Биологически активный комплекс, содержащий фосфолипиды, для терапевтического использования | |
| ATE299704T1 (de) | Warmgeformte feste arzneizusammensetzung zur gesteuerten wirkstoffabgabe von perindopril | |
| CO5300464A1 (es) | Metodo para regular la angiogenesis utilizando proteina ryk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |